AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Corvus Pharmaceuticals, Inc. Director's Dealing 2020

Dec 17, 2020

32755_dirs_2020-12-17_c0fd4383-5b0d-464d-9e69-6a88d737c998.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2020-12-16

Reporting Person: MILLER RICHARD A MD (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-16	Stock Option (Right to Buy)	$4.01	A	320000	Acquired	2030-12-16	Common Stock (320000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 16, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.